IMAX seen poised for stronger second half despite expected modest Q2

The market is likely underpricing how skewed IMAX’s earnings power is to the release calendar and premium-format mix, not to near-term quarterly growth. If the second half of 2026 improves as expected, the operating leverage can be meaningful because the model converts incremental attendance and system activity into disproportionately higher cash flow with limited fixed-cost drag. That makes the stock more of a long-duration content and distribution bet than a simple post-earnings trade.

Relative to theater peers, IMAX is the cleaner way to own a box-office recovery because it monetizes premium demand without taking the same balance-sheet and occupancy risk as exhibitors. A stronger slate helps CNK and other venue owners on traffic, but it helps IMAX more on margin per screen and on license/fee intensity; weaker chains are more exposed if the consumer merely trades down to premium screens rather than expands overall visits. The second-order risk is that any slip in studio scheduling or a soft macro backdrop would push the hoped-for 2H26 acceleration further out, which would compress the multiple quickly given the stock already trades on forward improvement.

The contrarian point is that the bullish setup may be real but not immediately tradable: the stock can look cheap versus a target while still being dead money until there is visible evidence that the 2026 slate is firming. The key falsifier is not analyst tone; it is whether upcoming box office bookings, screen growth, and management commentary confirm a better 2H26 path over the next 1-2 earnings cycles. Without that, the upside is probably capped and the equity is vulnerable to multiple contraction if growth stays merely modest.